Home > Pulmonology > Solriamfetol effective for treating excessive daytime sleepiness

Solriamfetol effective for treating excessive daytime sleepiness


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Sleep Medicine
Reuters Health - 06/10/2020 - The selective norepinephrine-dopamine-reuptake inhibitor solriamfetol is well-tolerated and effective for treating excessive daytime sleepiness (EDS) in patients with narcolepsy or obstructive sleep apnea (OSA), according to a systematic review and meta-analysis. "Solriamfetol appears to be more effective and safer than the other current medications prescribed for excessive sleepiness based on the evidence," Dr. Roshan Subedi of Tribhuvan University Teaching Hospital in Kathmandu, Nepal, told Reuters Health by email. EDS, defined as the inability to maintain wakefulness and alertness during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times almost daily for at least three months, is a common symptom of narcolepsy and OSA. Solriamfetol was approved by the U.S. Food and Drug Administration for EDS related to narcolepsy and OSA in March 2019. Dr. Subedi and colleagues evaluated the s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on